JonXu
2021-05-24
Right now position
Biotech M&A could soon pick up following slow 2021 start - Jefferies<blockquote>继2021年开局缓慢之后，生物技术并购可能很快就会回升-Jefferies</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":131006069,"tweetId":"131006069","gmtCreate":1621815058151,"gmtModify":1634186471425,"author":{"id":3575937002491607,"idStr":"3575937002491607","authorId":3575937002491607,"authorIdStr":"3575937002491607","name":"JonXu","avatar":"https://static.tigerbbs.com/676f4f2e7860b5b1ac8bc8330a688bd8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":4,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Right now position </p></body></html>","htmlText":"<html><head></head><body><p>Right now position </p></body></html>","text":"Right now position","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/131006069","repostId":1197866832,"repostType":4,"repost":{"id":"1197866832","kind":"news","pubTimestamp":1621814204,"share":"https://www.laohu8.com/m/news/1197866832?lang=zh_CN&edition=full","pubTime":"2021-05-24 07:56","market":"us","language":"en","title":"Biotech M&A could soon pick up following slow 2021 start - Jefferies<blockquote>继2021年开局缓慢之后，生物技术并购可能很快就会回升-Jefferies</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1197866832","media":"seekingalpha","summary":"Biotech M&A, which has been relatively quiet so far this year, is poised to pick up due to more reas","content":"<p>Biotech M&A, which has been relatively quiet so far this year, is poised to pick up due to more reasonableprices for biotech companies, according to Jefferies analyst Michael Yee.</p><p><blockquote>杰富瑞(Jefferies)分析师Michael Yee表示，今年迄今为止，生物技术并购相对平静，但由于生物技术公司的价格更加合理，生物技术并购有望回升。</blockquote></p><p> \"Typically, we see 3-5 [month] corrections…[and] then pharma starts to step in and finalize deals,” he wrote in a note on Friday. \"We are now 3 months into a large drawdown and down 30% off highs.\"</p><p><blockquote>“通常情况下，我们会看到3-5个月的调整……然后制药公司开始介入并敲定交易，”他在周五的一份报告中写道。“我们现在已经大幅缩水3个月了，较高点下跌了30%。”</blockquote></p><p> The biggest biotech M&A deal so far this year was Jazz Pharmaceuticals'(NASDAQ:JAZZ)$7.2B acquisitionof GW Pharmaceuticals announced in February.</p><p><blockquote>今年迄今为止最大的生物技术并购交易是Jazz Pharmaceuticals（纳斯达克股票代码：JAZZ）于2月份宣布以72亿美元收购GW Pharmaceuticals。</blockquote></p><p> The second largest deal was Horizon Therapeutics'(NASDAQ:HZNP)$3.05B acquisition of Viela Biowhich closed in March.</p><p><blockquote>第二大交易是Horizon Therapeutics（纳斯达克股票代码：HZNP）以30.5亿美元收购Viela Bio，该交易于3月份完成。</blockquote></p><p> Yee cites Horizon as a potential acquisition target.</p><p><blockquote>Yee将Horizon列为潜在收购目标。</blockquote></p><p> Others on his radar are: Arrowhead Pharmaceuticals(NASDAQ:ARWR), Ultragenix Pharmaceutial(NASDAQ:RARE), Iovance Biotherapeutics(NASDAQ:IOVA), Allakos(NASDAQ:ALLK), Fate Therapeutics(NASDAQ:FATE), and TG Therapeutics(NASDAQ:TGTX).</p><p><blockquote>他关注的其他公司包括：Arrowhead Pharmaceuticals（纳斯达克：ARWR）、Ultragenix Pharmaceutial（纳斯达克：RARE）、Iovance Biotherapeutics（纳斯达克：IOVA）、Allakos（纳斯达克：ALLK）、Fate Therapeutics（纳斯达克：FATE）和TG Therapeutics（纳斯达克：TGTX）。</blockquote></p><p> Yee also said Biogen(NASDAQ:BIIB), one of the larger biotech names, could be acquired.</p><p><blockquote>Yee还表示，可能会收购规模较大的生物技术公司之一Biogen（纳斯达克股票代码：BIIB）。</blockquote></p><p> The last mega biotech deal was in December 2020 withAstraZeneca's(NASDAQ:AZN) $39B acquisition of Alexion.</p><p><blockquote>最后一笔大型生物技术交易是在2020年12月，阿斯利康（纳斯达克：AZN）以39B美元收购Alexion。</blockquote></p><p> Year-to-date, the iShares Biotechnology ETF(NASDAQ:IBB)has no change and the SPDR Biotech ETF(NYSEARCA:XBI)is down 10%.</p><p><blockquote>今年迄今为止，iShares生物技术ETF（纳斯达克：IBB）没有变化，SPDR生物技术ETF（NYSEARCA：XBI）下跌了10%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech M&A could soon pick up following slow 2021 start - Jefferies<blockquote>继2021年开局缓慢之后，生物技术并购可能很快就会回升-Jefferies</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech M&A could soon pick up following slow 2021 start - Jefferies<blockquote>继2021年开局缓慢之后，生物技术并购可能很快就会回升-Jefferies</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">seekingalpha</strong><span class=\"h-time small\">2021-05-24 07:56</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Biotech M&A, which has been relatively quiet so far this year, is poised to pick up due to more reasonableprices for biotech companies, according to Jefferies analyst Michael Yee.</p><p><blockquote>杰富瑞(Jefferies)分析师Michael Yee表示，今年迄今为止，生物技术并购相对平静，但由于生物技术公司的价格更加合理，生物技术并购有望回升。</blockquote></p><p> \"Typically, we see 3-5 [month] corrections…[and] then pharma starts to step in and finalize deals,” he wrote in a note on Friday. \"We are now 3 months into a large drawdown and down 30% off highs.\"</p><p><blockquote>“通常情况下，我们会看到3-5个月的调整……然后制药公司开始介入并敲定交易，”他在周五的一份报告中写道。“我们现在已经大幅缩水3个月了，较高点下跌了30%。”</blockquote></p><p> The biggest biotech M&A deal so far this year was Jazz Pharmaceuticals'(NASDAQ:JAZZ)$7.2B acquisitionof GW Pharmaceuticals announced in February.</p><p><blockquote>今年迄今为止最大的生物技术并购交易是Jazz Pharmaceuticals（纳斯达克股票代码：JAZZ）于2月份宣布以72亿美元收购GW Pharmaceuticals。</blockquote></p><p> The second largest deal was Horizon Therapeutics'(NASDAQ:HZNP)$3.05B acquisition of Viela Biowhich closed in March.</p><p><blockquote>第二大交易是Horizon Therapeutics（纳斯达克股票代码：HZNP）以30.5亿美元收购Viela Bio，该交易于3月份完成。</blockquote></p><p> Yee cites Horizon as a potential acquisition target.</p><p><blockquote>Yee将Horizon列为潜在收购目标。</blockquote></p><p> Others on his radar are: Arrowhead Pharmaceuticals(NASDAQ:ARWR), Ultragenix Pharmaceutial(NASDAQ:RARE), Iovance Biotherapeutics(NASDAQ:IOVA), Allakos(NASDAQ:ALLK), Fate Therapeutics(NASDAQ:FATE), and TG Therapeutics(NASDAQ:TGTX).</p><p><blockquote>他关注的其他公司包括：Arrowhead Pharmaceuticals（纳斯达克：ARWR）、Ultragenix Pharmaceutial（纳斯达克：RARE）、Iovance Biotherapeutics（纳斯达克：IOVA）、Allakos（纳斯达克：ALLK）、Fate Therapeutics（纳斯达克：FATE）和TG Therapeutics（纳斯达克：TGTX）。</blockquote></p><p> Yee also said Biogen(NASDAQ:BIIB), one of the larger biotech names, could be acquired.</p><p><blockquote>Yee还表示，可能会收购规模较大的生物技术公司之一Biogen（纳斯达克股票代码：BIIB）。</blockquote></p><p> The last mega biotech deal was in December 2020 withAstraZeneca's(NASDAQ:AZN) $39B acquisition of Alexion.</p><p><blockquote>最后一笔大型生物技术交易是在2020年12月，阿斯利康（纳斯达克：AZN）以39B美元收购Alexion。</blockquote></p><p> Year-to-date, the iShares Biotechnology ETF(NASDAQ:IBB)has no change and the SPDR Biotech ETF(NYSEARCA:XBI)is down 10%.</p><p><blockquote>今年迄今为止，iShares生物技术ETF（纳斯达克：IBB）没有变化，SPDR生物技术ETF（NYSEARCA：XBI）下跌了10%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3699307-biotech-mergers-acquisitions-could-soon-pick-up-following-slow-2021-start-jefferies\">seekingalpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JAZZ":"爵士制药","IBB":"生物科技指数ETF-iShares Nasdaq","HZNP":"Horizon Pharma","XBI":"SPDR S&P Biotech ETF"},"source_url":"https://seekingalpha.com/news/3699307-biotech-mergers-acquisitions-could-soon-pick-up-following-slow-2021-start-jefferies","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1197866832","content_text":"Biotech M&A, which has been relatively quiet so far this year, is poised to pick up due to more reasonableprices for biotech companies, according to Jefferies analyst Michael Yee.\n\"Typically, we see 3-5 [month] corrections…[and] then pharma starts to step in and finalize deals,” he wrote in a note on Friday. \"We are now 3 months into a large drawdown and down 30% off highs.\"\nThe biggest biotech M&A deal so far this year was Jazz Pharmaceuticals'(NASDAQ:JAZZ)$7.2B acquisitionof GW Pharmaceuticals announced in February.\nThe second largest deal was Horizon Therapeutics'(NASDAQ:HZNP)$3.05B acquisition of Viela Biowhich closed in March.\nYee cites Horizon as a potential acquisition target.\nOthers on his radar are: Arrowhead Pharmaceuticals(NASDAQ:ARWR), Ultragenix Pharmaceutial(NASDAQ:RARE), Iovance Biotherapeutics(NASDAQ:IOVA), Allakos(NASDAQ:ALLK), Fate Therapeutics(NASDAQ:FATE), and TG Therapeutics(NASDAQ:TGTX).\nYee also said Biogen(NASDAQ:BIIB), one of the larger biotech names, could be acquired.\nThe last mega biotech deal was in December 2020 withAstraZeneca's(NASDAQ:AZN) $39B acquisition of Alexion.\nYear-to-date, the iShares Biotechnology ETF(NASDAQ:IBB)has no change and the SPDR Biotech ETF(NYSEARCA:XBI)is down 10%.","news_type":1,"symbols_score_info":{"HZNP":0.9,"IBB":0.9,"XBI":0.9,"JAZZ":0.9}},"isVote":1,"tweetType":1,"viewCount":340,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":16,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/131006069"}
精彩评论